Cash and cash equivalents, as of June 30, 2025, were $100.7 million compared to $102.7 million as of December 31, 2024. Based on current plans and assumptions, the Company expects that its existing cash and cash equivalents will be sufficient to fund operations into Q1 2027, including the Company’s expected submission of the BLA for CAN-2409 in intermediate-to-high-risk prostate cancer to the FDA in Q4 2026.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CADL:
- Candel Therapeutics receives EMA Orphan Designation for CAN-2409
- Candel Therapeutics: Promising Phase 3 Data and Strong Financial Runway Justify Buy Rating
- Candel Therapeutics initiated with a Buy at Brookline
- Candel Therapeutics announces addition to multiple Russell Indexes
- Candel Therapeutics assumed with a Buy at H.C. Wainwright